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ABSTRACT
Background: Chordomas are aggressive bone tumors that have a predilection for the axial 
skeleton including the skull base and spinal/sacral bones. However, the histopathological and 
clinical differences between skull base chordoma (SBC) and sacral/spinal chordoma (SC) are 
unclear as previous studies have been focused on patient prognosis and treatment outcome. 
This study aimed to evaluate the clinicopathologic features and prognosis of chordoma 
according to its location.
Methods: Patients with chordomas were enrolled, and the histopathologic features were 
compared according to the tumor location.
Results: A total of 52 patients were enrolled. SBCs had more abundant chondroid matrix 
and diffuse growth pattern, while SCs had non-chondroid, myxoid matrix and a lobulating 
pattern, typical of chordoma. Old age and residual tumors were risk factors for shorter overall 
survival in SBCs. The chondroid matrix was an independent risk factor for shorter disease-
free survival in the overall population.
Conclusion: Chordomas have different histopathologic features depending on the 
anatomical location.
Keywords: Chordoma; Notochord; Skull Base Neoplasms; Brain Neoplasms;  
Soft Tissue Neoplasms; Bone Neoplasms
INTRODUCTION
Chordomas are rare, aggressive bone tumors that occur in the axial skeleton. The 
sacrococcygeal region is the most common site, accounting for 65% of all cases 
of chordomas, followed by the spheno-occipital/nasal (25%), cervical (10%), and 
thoracolumbar (5%) spines.1 This tumor is thought to originate from notochordal remnants.2 
Histologically, chordomas are characterized by lobulated masses that are separated by thick 
fibrous septa. Tumors typically consist of physaliphorous cells that are arranged in cords or 
sheets within the abundant myxoid stroma. Histologically, there are three different subtypes 
of chordoma, namely, chondroid, dedifferentiated, and classical, with the chondroid type 
having better prognosis than the classical type.3
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Basic Medical Sciences
Because surgery of the skull base or sacral area is difficult due to the complex anatomy and 
adjacent critical structures, complete tumor resection is often impossible, and patients 
usually receive adjuvant therapy or radiotherapy like proton therapy.4 Thus, the benefit of 
adjuvant treatment according to the tumor location has been investigated.5-7 Meanwhile, few 
studies have conducted a detailed comparison of the histologic features of skull base and 
spinal/sacral chordomas. A previous study demonstrated that skull base chordoma (SBC) 
patients are significantly younger than non-SBC (NSBC) patients.8 Histologically, spinal 
chordoma shows increased proliferative capability,9 abundant intralesional fibrous septum 
and extracellular mucoid matrices, and a less frequent chondroid appearance.10 SBCs present 
with phagocytosis (hemosiderin deposits) more frequently than NSBCs.10
Yamaguchi et al.11 suggested a benign notochordal cell tumor (BNCT) as a precursor lesion 
of chordoma. BNCT is characterized by sheets of benign-looking, adipocyte-like large cells 
without intervening stroma. However, whether BNCT is a precursor or tumor component 
itself remains controversial,12,13 and the histologic evaluation and clinical implication of 
these components in chordomas are yet to be clarified.
This study aimed to evaluate the clinicopathological features and prognosis of chordomas 
according to its location. The patients were divided into two groups according to the location 
of the chordoma, and the clinicopathological variables were compared between the two 
groups. The prevalence of BNCT-like component in each location was also analyzed.
METHODS
Patients and ethical concerns
Patients with chordomas admitted to Samsung Medical Center between March 1996 and 
February 2015 were retrospectively enrolled. Data on the patients' age at initial diagnosis, 
gender, tumor size, type of tumor resection (complete or incomplete), and postoperative 
adjuvant treatment were obtained from medical records. Magnetic resonance images of all 
the patients were reviewed to identify the tumor location. Chordomas were divided into two 
groups: SBCs and sacral/spinal chordomas (SCs). The SBCs included tumors of the clivus, 
sphenoid, spheno-occipital, sella/parasellar regions, petrosal part of the temporal bone, and 
intradural chordomas. Meanwhile, SCs included tumors of the spine and sacrococcygeal 
regions. For SBCs, tumor extension beyond the clivus or skull base was defined as an 
extracranial extension.
Histopathologic analysis
Histologic examination was performed using hematoxylin and eosin (H&E)-stained slides. All 
slides were retrospectively reviewed by two pathologists. The following histologic parameters 
were evaluated: tumor matrix (chondroid or myxoid [non-chondroid]), growth pattern 
(lobulating or diffuse), necrosis, presence and proportion of BNCT-like component, nuclear 
pleomorphism, and intracytoplasmic hyaline globules. Chondroid matrix was defined as bluish 
homogeneous matrix reminiscent of hyaline cartilaginous matrix, which was distinguished 
from eosinophilic, pinkish secretory materials or myxoid matrix (Fig. 1A). Lobulating growth 
pattern was assessed when obvious intralesional fibrous septa were identified under a low-
power magnification (Fig. 1B). BNCT-like component was defined as sheets of large uni- or 
multivacuolated adipocyte-like cells with eccentrically located small nuclei and lacked the 
intervening tumor matrix (Fig. 1C). Nuclear pleomorphism was evaluated according to the 
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following criteria: absent, small bland looking nuclei with inconspicuous nucleoli; present, 
enlarged nuclei having prominent nucleoli and membrane irregularity.
Immunohistochemical staining for Ki-67
To evaluate the proliferative activity of tumors, Ki-67 immunohistochemistry was performed 
for each tumor. Sections from formalin-fixed paraffin-embedded tissue were used for 
immunohistochemistry with antibodies against Ki-67 (clone MIB-1; 1:1,000; Abcam, 
Cambridge, UK). Briefly, 4-µm-thick paraffin sections were deparaffinized and rehydrated 
using xylene and alcohol solution. Immunohistochemistry was performed using the Ventana 
Discovery XT automated stainer (Ventana Medical System, Tucson, AZ, USA). Antigen 
retrieval was performed using cell conditioning 1 buffer (citrate buffer Ph 6.0, Ventana 
Medical System). Appropriate positive and negative controls for immunohistochemistry were 
included. The findings of immunohistochemical staining of all cases were assessed with 
eyeball interpretation method by two pathologists using light microscopes.
Statistical analysis
Results were expressed as mean ± standard deviation. Data were analyzed using SPSS for 
Windows (version 18.0; SPSS Inc., Chicago, IL, USA). Mann-Whitney U test and Kruskal-
Wallis test were used to compare continuous variables, and Pearson's χ2 tests and Fisher's 
exact tests were used to compare categorical variables. Wilcoxon signed-rank tests were 
used to compare matched variables. Logistic regression analysis was used to assess the risk 
factors for death and recurrence. Disease-free survival (DFS) was calculated from the date of 
the first surgery to the date of the first regional or systemic relapse. Overall survival (OS) was 
estimated from the date of the first surgery to the date of the last follow-up or death from any 
cause. Cox proportional hazard model was used to assess the risk factors for overall survival 
and disease-free survival, and patients who were followed-up over 6 months were included 
for analysis. Kaplan-Meier survival curves and log-rank statistics were employed to evaluate 
time to survival. P < 0.05 was considered significant.
Ethics statement
This study was approved by the Institutional Review Board of Samsung Medical Center with a 
waiver of informed consent (No. 2015-02-071).
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A B C
Fig. 1. Characteristic histologic features of chordomas. (A) Chondroid matrix is frequently found in clival/intradural chordomas. (B) Fibrous septae with 
lobulating pattern is often observed in spinal/sacral chordomas. (C) BNCT-like area in clival chordoma. The cells resemble mature adipocytes and have 
eccentrically located small nuclei. Hyaline globules, one of the features of BNCT, are occasionally observed in BNCT-like areas of chordomas (inlet). 
BNCT = benign notochordal cell tumor.
RESULTS
Comparison of clinicopathologic profile of patients between SBCs and SCs
In total, 52 patients were included in the analysis. Of them, 32 (61.5%) were men, and 20 
(38.5%) were women. The mean age was 54.4 years (range, 18–82 years). The course of 
disease duration ranged from 1 to 276 months (average, 57.4 months). Regarding tumor 
location, 32 patients (61.5%) and 20 patients, (38.5%) had SBCs and SCs, respectively. The 
clinicopathologic features of the patients with SBCs and SCs are shown in Table 1. There was 
no dedifferentiated chordoma in the present cohort. Most of the SBCs affected the clivus 
(27 cases, 84.4%), from which extracranial extension was found in 17 patients. There were 
3 cases of intradural chordoma. Extracranial extension of the tumor affected the sphenoid 
bone, pterygoid bone, and nasopharynx. Meanwhile, the most frequently affected region in 
SCs was the sacrococcygeal region (16 cases), followed by the cervical (3 cases) and thoracic 
spines (1 case). The mean age at diagnosis of the patients with SBCs was younger (53.5 years) 
than those with SCs (57.7 years). Meanwhile, the mean size of the tumors was significantly 
larger in SCs (65.4 mm) than that in SBCs (40.5 mm). Death and tumor recurrence were more 
common in SBCs than those in SCs (28.1% and 37.5% vs. 15% and 25%). Forty-four patients 
(84.6%) underwent surgical resection. The total resection rate was lower in SBCs (46.4%) 
than that in SCs (68.8%). Among patients who underwent surgical resection, complete 
resection without residual tumor was achieved in only approximately 50%. Adjuvant therapy 
including radiotherapy and proton therapy after biopsy or surgical resection was given in 
approximately 50% and 65% of patients with SBC and SC, respectively. The 5-year survival 
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Table 1. Clinicopathologic characteristics based on anatomical location and tumor extent
Parameters Clivus/intradura  
(n = 15)
Clivus with 
extracranial extension 
(n = 17)
Spine/sacrum  
(n = 20)
P value
Clinical parameters
Age, yr 53.13 ± 15.01 53.82 ± 16.39 57.70 ± 12.79 0.696
Genger, men 10 (66.7) 9 (52.9) 13 (65.0) 0.721
Tumor size, mma 30.79 ± 12.33 49.12 ± 18.03 65.37 ± 26.79 < 0.001
Death 3 (20.0) 6 (35.3) 3 (15.0) 0.384
Recurrence 4 (26.7) 8 (47.1) 5 (25.0) 0.347
Follow-up period, mon 45.74 ± 57.27 50.98 ± 43.13 71.60 ± 63.30 0.306
Treatment 0.071
Biopsy only 0 (0.0) 4 (23.5) 4 (20.0)
Partial surgical removal 10 (66.7) 5 (29.4) 5 (25.0)
Total surgical removal 5 (33.3) 8 (47.1) 11 (55.0)
Adjuvant treatment 0.297
None 8 (53.3) 8 (47.1) 7 (35.0)
Stereotactic 
radiosurgery
2 (13.3) 5 (29.4) 1 (5.0)
Proton therapy 1 (6.7) 1 (16.7) 4 (20.0)
Radiation therapy 4 (26.7) 3 (17.6) 8 (40.0)
Histopathologic parameters
Nuclear pleomorphism 4 (26.7) 4 (23.5) 8 (40.0) 0.522
BNCT-like component 5 (33.3) 5 (38.5) 7 (43.8) 0.925
Hyaline globules 4 (26.7) 2 (11.8) 5 (25.0) 0.529
Necrosis 2 (13.3) 7 (41.2) 8 (40.0) 0.177
Chondroid matrixa 13 (86.7) 11 (84.6) 7 (43.8) 0.020
Diffuse growth patterna 12 (80.0) 9 (75.0) 2 (14.3) < 0.001
Ki-67 LI in chordoma area, % 2.30 ± 2.84 2.83 ± 3.73 3.16 ± 4.59 0.968
Ki-67 LI in BNCT-like area, % 0.86 ± 1.46 1.33 ± 2.81 0.20 ± 0.45 0.718
Data are presented as mean ± standard deviation or number (%).
LI = labeling index, BNCT = benign notochordal cell tumor.
aP < 0.05.
rate was lower for patients with SBCs than that for patients with SCs (78.1% vs. 95.0%), 
but not statistically significant. Other parameters including age, gender, patient death, and 
tumor recurrence were not significantly different between the two groups.
Regarding histopathological features, the lobulating pattern was more significantly common 
in SCs (85.7%) than that in SBCs (34.4%). Chondroid matrix was observed more frequently in 
SBCs (75%) than in SCs (43.8%). Meanwhile, nuclear atypia and necrosis tended to be more 
frequently found in SCs, but the frequency is not significantly different. BNCT-like features 
were observed in 37.5% (12/32) of SBCs and 25.0% (5/20) of SCs. Hyaline globules were found 
in 18.8% (6/32) of SBCs and 25.0% (5/20) of SCs. For the mean Ki-67 labeling index (LI), no 
significant difference was found between SBCs (mean, 2.6%) and SCs (mean, 3.2%). The 
Ki-67 LI of tumors and BNCT-like areas showed no significant difference according to the 
tumor location. However, a comparison of the Ki-67 LI of tumors and BNCT-like areas in each 
patient showed that large cells of BNCT-like areas tended to show a lower Ki-67 LI than those 
of typical chordoma areas (0.83% ± 1.82% vs. 2.28% ± 3.70%; P = 0.063).
Risk factors for mortality and recurrence in SBCs and SCs
In univariate logistic analysis, residual tumor was the only risk factor for patients' death in 
SBCs (Table 2). History of adjuvant treatment and presence of BNCT-like component were 
independent negative risk factors for recurrence in SBCs (Table 3). No significant variables 
associated with death or recurrence was observed in SCs.
In SBCs, older age and residual tumors were risk factors for shorter OS, and older age was 
the only independent risk factor for shorter OS (Table 4). No significant risk factor was 
found in SCs. There was no significant risk factor for shorter DFS in both SBCs and SCs. 
Only chondroid matrix seemed to be the risk factor for shorter DFS in SCs, but it was not 
significant (Table 5).
In the overall analysis regardless of tumor location, older age was the only independent risk 
factor for shorter OS, and chondroid matrix was the only independent risk factor for shorter 
DFS. The OS was not significantly different between patients with SBCs and SCs. However, 
the patients with SBCs showed significantly shorter DFS than those with SCs (Fig. 2).
When all patients were analyzed together, risk factors for short OS was age, which was 
significant in univariate and multivariate analysis (Table 6). For risk factors of short DFS, 
chondroid matrix was an only significant factor by univariate and multivariate analysis in all 
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Table 2. Risk factors for patients' death on univariate analysis
Variables Clivus/intradura Spinal/sacrum
β ± SE P value β ± SE P value
Age, yr 0.061 ± 0.035 0.085 −0.003 ± 0.05 0.956
Size 0.017 ± 0.022 0.437 0.009 ± 0.023 0.693
Residual tumora 2.342 ± 1.141 0.040 −0.811 ± 1.318 0.538
Adjuvant treatment −0.665 ± 0.795 0.403 −0.336 ± 1.320 0.799
BNCT-like component −1.992 ± 1.140 0.080 −19.817 ± 17,974.843 0.999
Necrosis 0.348 ± 0.852 0.683 −0.336 ± 1.320 0.799
Chondroid matrix −1.204 ± 0.940 0.200 1.299 ± 1.326 0.327
Diffuse growth pattern 0.336 ± 0.936 0.719 −19.593 ± 23,205.422 0.999
Ki-67 LI 0.033 ± 0.117 0.777 −0.249 ± 0.319 0.435
β = standardized coefficients, BNCT = benign notochordal cell tumor, LI = labeling index.
aP < 0.05.
patients (Table 7). Clinvus/intradural location of tumor was a significant risk factor of short 
DFS by univariate analysis but not significant by multivariate analysis (Table 7).
DISCUSSION
The present study investigated the clinicopathological features between SBCs and SCs 
and found that extracranial extension is frequent in SBCs affecting the clivus. SBCs were 
significantly smaller in size than SCs. Because the skull base is narrower than the sacrum 
and surrounded by cranial nerves, blood vessels, and bones, the clinical manifestations may 
develop earlier in patients with SBCs than in those with SCs, even in patients with smaller 
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Table 3. Risk factors for recurrence based on location
Variables Univariate Multivariate
Clivus/intradura Spine/sacrum Clivus/intradura
β ± SE P value β ± SE P value β ± SE P value
Age, yr −0.009 ± 0.024 0.702 0.011 ± 0.042 0.788 - -
Size 0.020 ± 0.021 0.350 −0.006 ± 0.021 0.788 - -
Residual tumor −0.405 ± 0.736 0.582 −0.539 ± 1.049 0.608 - -
Adjuvant treatmenta −2.197 ± 0.843 0.009 0.000 ± 1.054 1.000 −2.005 ± 0.924 0.030
Necrosis 0.405 ± 0.801 0.613 0.000 ± 1.054 1.000 - -
BNCT-like componenta −2.599 ± 1.137 0.022 0.981 ± 1.118 0.380 −2.939 ± 1.207 0.047
Chondroid matrix −0.636 ± 0.915 0.487 1.099 ± 1.065 0.302 - -
Diffuse growth pattern 0.208 ± 0.838 0.804 0.405 ± 1.394 0.771 - -
Ki-67 LI −0.031 ± 0.115 0.787 0.003 ± 1.115 0.979 - -
β = standardized coefficients, SE = standard error, BNCT = benign notochordal cell tumor, LI = labeling index.
aP < 0.05 by univariate and multivariate analyses.
Table 4. Risk factors for shorter overall survival as assessed on Cox proportional hazard analysis
Variables Univariate Multivariate
Clivus/intradura Spine/sacrum Clivus/intradura
HR 95% CI P value HR 95% CI P value HR 95% CI P value
Age, yra 1.071 1.007–1.138 0.029 1.026 0.930–1.133 0.607 11.610 1.425–94.626 0.022
Size 1.009 0.974–1.045 0.622 1.008 0.967–1.051 0.703 - - -
Residual tumorb 11.610 1.430–94.630 0.022 0.281 0.025–3.178 0.305 - - -
Adjuvant treatment 0.793 0.195–3.219 0.745 1.338 0.120–14.961 0.813 - - -
Necrosis 0.902 0.223–3.652 0.885 0.823 0.074–9.118 0.874 - - -
BNCT-like component - - - - - - - - -
Chondroid matrix 0.584 0.137–2.489 0.467 4.696 0.424–52.019 0.208 - - -
Diffuse growth pattern - - - - - - - - -
Ki-67 LI 1.062 0.892–1.265 0.499 0.813 0.455–1.452 0.484 - - -
HR = hazard ratio, CI = confidence interval, BNCT = benign notochordal cell tumor, LI = labeling index.
aP < 0.05 by univariate and multivariate analyses; bP < 0.05 by univariate analysis only.
Table 5. Risk factors for shorter disease-free survival on Cox proportional hazard analysis
Variables Clivus/intradura Spine/sacrum
HR 95% CI P value HR 95% CI P value
Age, yr 1.015 0.983–1.049 0.354 1.025 0.952–1.104 0.511
Size 1.008 0.974–1.043 0.660 0.995 0.962–1.028 0.755
Residual tumor 2.451 0.714–8.412 0.154 0.174 0.018–1.715 0.134
Adjuvant treatment 2.957 0.771–11.334 0.114 2.119 0.216–20.801 0.519
Necrosis 0.846 0.253–2.825 0.785 0.472 0.048–4.632 0.519
BNCT-like component 0.173 0.022–1.362 0.096 1.110 0.112–11.029 0.929
Chondroid matrix 1.134 0.305–4.216 0.851 9.305 0.962–90.014 0.054
Diffuse growth pattern 1.415 0.364–5.505 0.616 0.023 0.000–406.493 0.451
Ki-67 LI 1.071 0.908–1.264 0.416 1.155 0.916–1.457 0.224
HR = hazard ratio, CI = confidence interval, BNCT = benign notochordal cell tumor, LI = labeling index.
SBC lesions. Regarding histopathological parameters, the lobulating growth pattern typical 
of classical chordoma was less frequent in SBCs, while the diffuse growth pattern and 
chondroid matrix were more common in SBCs than in SCs. These different histopathological 
findings of SBCs were also observed in a previous study by Naka et al.14 In another study by 
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Fig. 2. Overall survival and disease-free survival based on tumor location. Overall survival (A) tends to be lower in patients with clival/intradural chordomas than 
in those with spinal/sacral chordomas, although the difference is not statistically significant. However, disease-free survival (B) of patients with clival/intradural 
chordomas is significantly lower than that of those with spinal/sacral chordomas.
Table 6. Risk factors for shorter overall survival for all patients on Cox proportional hazard analysis
Variables Univariate Multivariate
HR 95% CI P value HR 95% CI P value
Age, yra 1.048 1.001–1.097 0.046 1.048 1.001–1.097 0.046
Size 0.998 0.976–1.020 0.836 - - -
Residual tumor 2.681 0.720–9.992 0.142 - - -
Adjuvant treatment 0.924 0.287–2.972 0.894 - - -
Necrosis 0.876 0.263–2.921 0.830 - - -
Large cell 0.260 0.034–2.023 0.198 - - -
BNCT-like component 1.757 0.525–5.883 0.361 - - -
Diffuse growth pattern 1.066 0.293–3.885 0.923 - - -
Ki67 LI 1.006 0.857–1.180 0.945 - - -
Clivus/intradural location 2.844 0.747–10.824 0.125 - - -
HR = hazard ratio, CI = confidence interval, BNCT = benign notochordal cell tumor, LI = labeling index.
aP < 0.05 by univariate and multivariate analyses.
Table 7. Risk factors for shorter disease-free survival for all patients on Cox proportional hazard analysis
Variables Univariate Multivariate
HR 95% CI P value HR 95% CI P value
Age, yr 1.008 0.978–1.040 0.601 - - -
Size 0.990 0.971–1.009 0.292 - - -
Residual tumor 0.732 0.272–1.968 0.536 - - -
Adjuvant treatment 2.661 0.853–8.301 0.092 - - -
Necrosis 0.667 0.232–1.924 0.454 - - -
BNCT-like component 0.365 0.083–1.611 0.183 - - -
Chondroid matrixa 3.560 1.142–11.098 0.029 3.560 1.142–11.098 0.029
Diffuse growth pattern 1.204 0.415–3.491 0.733 - - -
Ki67 LI 1.082 0.944–1.241 0.258 - - -
Clivus/intradural locationb 3.461 1.086–11.031 0.036 - - -
HR = hazard ratio, CI = confidence interval, BNCT = benign notochordal cell tumor, LI = labeling index.
aP <0.05 by univariate and multivariate analyses; bP < 0.05 by univariate analysis only.
Naka et al.,9 they demonstrated that the lobulation of chordoma is associated with nuclear 
pleomorphism and higher proliferative index, but also more favorable prognosis. The authors 
hypothesized that as the tumor progressed, the lobulation pattern would be replaced by 
diffuse growth pattern that would be related with poorer prognosis.9 In the present study, 
diffuse growth pattern was correlated with higher Ki-67 LI in clival/intradural chordomas, 
which also might reflect the tumor aggressiveness. Although no direct correlation was found 
between growth patterns itself and death or recurrence, it could partly be the cause of shorter 
DFS in SBCs.
As chondroid matrix was an independent risk factor for shorter DFS, it seems to be related 
with shorter DFS of SBCs. Although the surgical approach and total tumor resection are 
difficult in SBCs, residual tumors were not an independent risk factor of recurrence in 
multivariate analysis. Furthermore, in case of small biopsy specimen, chondrosarcoma 
would be the important differential diagnosis of SBC as chondroid matrix is frequently found 
in both tumors. Positive for cytokeratin immunohistochemical staining and the midline 
location favor the diagnosis of chordoma over chondrosarcoma in those cases. Chondroid 
chordoma was originally described as a variant of chordoma that contained cartilaginous 
areas indistinguishable from hyaline type chondrosarcoma, and they have better prognosis 
than non-chondroid chordomas.3 However, the immunohistochemical and ultrastructural 
features of chondroid chordomas are similar to those of classical chordomas.15
In the present study, the frequency of BNCT-like component was not different between SBCs 
and SCs. Unlike previous studies that focused on BNCT,11,16-18 our study is different in that 
we preferentially included chordoma cases at the beginning of the study, whereas BNCT is a 
benign aggregation of cells that originated from embryonic notochords; it is thought to be a 
potential precursor of chordoma.13 Some studies showed that the radiologic, histologic, and 
immunohistological features of BNCT vary19,20; however, whether BNCT is a real precursor of 
chordoma remain controversial.21
In the present study, we evaluated BNCT-like component that mimicked the histology of 
true BNCT, that is, a lower Ki-67 LI than that of typical chordoma. However, although 
the Ki-67 LI of BNCT-like area was lower than that of typical chordoma area, but the 
difference was not significant. Thus, we assumed that this BNCT-like component is also a 
tumor component although histologically it resembled true BNCT, including even having 
cytoplasmic hyaline globules that have been reported to be found in true BNCT. Interestingly, 
three cases of intradural chordomas were included in our study. Intradural chordomas are 
rare and have been reported to have better prognosis than conventional chordomas.22,23 
In the study by Wang et al.,24 three of the six intratumoral chordomas showed large-sized 
cells with abundant cytoplasm and little extracellular mucus-like matrix, which is similar 
to the histology of BNCT. Moreover, in the current study, all three patients with intradural 
chordoma were alive and did not experience recurrence, and two of them had BNCT-like 
component along with hyaline globules. Furthermore, intradural chordoma is more likely 
to achieve gross total resection, which also could contribute the favorable prognosis of 
intradural chordoma in this study.
SC patients showed longer OS and DFS than those with SBC, but the OS was not statistically 
significant. These results are in contrast to previous findings that sacral chordomas have 
worse prognosis. This discordance might be due to the difference in treatment modalities 
between the two studies. In the present study, over 50% of sacral chordoma patients 
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received complete surgical resection, whereas only 33% (4/12) of patients received gross total 
resection in the previous study.8 However, both previous and current studies analyzed only a 
small number of patients treated with variable modalities, and thus the results lack statistical 
power. Further studies with larger number of patients are needed.
In conclusion, our results highlight the histopathologic differences of chordomas based on 
anatomical location, which have not been thoroughly investigated previously. Regarding 
tumor location, clival/intradural chordomas are characterized by chondroid matrix and 
diffuse growth pattern, whereas spinal/sacral chordomas showed lobulating pattern. 
Pathologists should be aware that BNCT-like component may present in up to one-third of 
chordomas and should thus be diagnosed carefully.
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